Skip to content

Progenics Pharmaceuticals Inc

CIK 0000835887

← back to feed
Revenue (TTM)
$67.79M
+44.2% YoY Q1 May 2020
Net Income (TTM)
−$74.08M
−1.3% YoY Q1 May 2020
EPS Diluted (TTM)
$0.67
−2,075.0% YoY Q1 May 2020
Gross Margin
95.3%
Q1 May 2020
Operating Margin
-105.2%
Q1 May 2020
Net Margin
-109.3%
Q1 May 2020
Free Cash Flow (TTM)
−$57.33M
Q1 May 2020
Cash
$29.53M
Q1 May 2020
Total Debt
$37.41M
Q1 May 2020
Shares Outstanding
86.6M sh
Q1 May 2020

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings